Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIB/IV nonsmall cell lung carcinoma

Cancer

Volumn 95, Issue 7, 2002, Pages 1520-1527

  Socinski, Mark A ^a   Sandler, Alan B ^b   Israel, Valerie K ^c   Gillenwater, Heidi H ^a   Miller, Langdon L ^d   Locker, Paula K ^d   Antonellini, Alessandro ^d   Elfring, Gary L ^d   Natale, Ronald B ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Synergy Hematology Oncology Medical Associates   (United States)

^d PFIZER INC   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Chemotherapy; Irinotecan; Nonsmall cell lung carcinoma; Paclitaxel

Indexed keywords

ATROPINE; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; IBUPROFEN; IRINOTECAN; LORAZEPAM; ONDANSETRON; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PACLITAXEL; SURVIVAL ANALYSIS; VOMITING;

EID: 0036784447     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10852     Document Type: Article

References (46)

1. Greenlee RT, Hill-Harmon MD, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Ihde DC, Minna JD. Non-small cell lung cancer. Part I: biology, diagnosis, and staging. Curr Probl Cancer. 1991;15:61-104.
3. Clinical practice guideline for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996-3018.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
5. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer. 1995;71:366-370.
6. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer. 1989;60:764-766.
7. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer. 1989;58:359-361.
8. Tummarello D, Graziano F, Isidori P, Cellorino R. Symptomatic, Stage IV, non-small cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol. 1995;35:249-253.
9. Bunn PA Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;5:1807-1100.
10. Belani CP, Natale RB, Lee JS, et al. Randomized Phase III trial comparing cisplatin-etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) [abstract]. Pro Am Soc Clin Oncol. 1998;17:455a.
11. Kelly K, Crowley J, Bunn PA, et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218.
12. Schiller JH, Harrington D, Sandler A, et al. A randomized Phase III of four chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2000;19:1a.
13. Gatzemeier U, Rosell R, Betticher D, et al. Randomized pan-European trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer [abstract]. Eur J Cancer. 1999;35(Suppl 4):246.
14. Johnson DH, Zhu J, Schiller JH, et al. E 1594 - A randomized Phase III trial in metastatic non-small cell lung cancer (NSCLC) - outcome of PS 2 patients (pts): an Eastern Cooperative Group Trial (ECOG) [abstract]. Proc Am Soc Clin Oncol. 1999;18:461a.
15. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873-14878.
16. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722-1726.
17. Negoro S, Fukuoka M, Niitani H, et al. A Phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother. 1991;18:1013-1019.
18. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst. 1991;83:1164-1168.
19. Nakai H, Fukuoka M, Furuse K, et al. An early Phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother. 1991;18:607-612.
20. Fukuoka M, Negoro S, Niitani H, et al. A Phase I study of weekly administration of CPT-11 in lung cancer. Jpn J Cancer Chemother. 1990;17:993-997.
21. Baker L, Khan R, Lynch T, et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Amer Soc Clin Oncol. 1997;16:461a.
22. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol. 1994;12:90-96.
23. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer. 1993;68:777-782.
24. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol. 1992;10:1775-1780.
25. DeVore RF, Johnson DH, Crawford J, et al. Phase II trial of irinotecan plus cisplatin in patients with advanced nonsmall cell lung cancer. J Clin Oncol. 1999;17:2710-2720.
26. Komiya T, Fukuoka M, Negoro S, et al. Randomized Phase III trial compared cisplatin and irinotecan (CPT-11) versus cisplatin and vindesine (VDS-P) versus irinotecan alone (CPT) in patients with advanced non-small cell lung cancer (NSCLC) - the final report [abstract]. Lung Cancer. 2000;29(Suppl):28.
27. Takiguchi Y, Nagao K, Nishiwaki A, et al. The final results of a randomized Phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer. 2000;29(Suppl):28.
28. Socinski MA, Sandler AB, Miller LL, et al: Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol. 2001;19:1078-1087.
29. Cockcroft DW, Gault MH. Predication of creatinine clearance from serum creatinine. Nephron. 1976;16:31-34.
30. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
31. Bleiberg H, Cvitkovic E. Characterization and clinical management of CPT-11 (irinotecan) induced adverse events: the European perspective. Eur J Cancer. 1996;32A(Suppl 3):S18-S23.
32. Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol. 1996;23:1000-1004.
33. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
34. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol. 1986;4:14-22.
35. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in Stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989;7:1602-1613.
36. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y. Inhibition of cis-diaminodichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer. 1995;62:70-75.
37. Fukuoka M, Kudoh S, Musuda N. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Assoc Cancer Res. 1992;33:226.
38. Pei X, Nakaniski Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-Cancer Drugs. 1997;8:231-237.
39. Hainsworth JD, Burris HA III, Erland JB, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer. 1999;85:1269-1276.
40. Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA Jr. A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000;6:3474-3479.
41. Hainsworth JD, Burris HA, Morrissey LH, et al. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a Phase II trial of the Minnie Pearl Cancer Research Network. Cancer J. 2000;6:151-156.
42. Fujita A, Takabatake H, Tagaki S, Sekine K. Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Oncology. 1999;6:301-307.
43. Fujita A, Takabatake H, Tagaki S, Sekine K. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with Stage IIIB/IV non-small cell lung cancer. Cancer Chemother Pharmacol. 2000;45:279-283.
44. Kiura K, Ueoka H, Eguchi K, et al. Phase I study of cisplatin, docetaxel and irinotecan for advanced non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer. 2000;29(Suppl 1):45.
45. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000;18:1451-1457.
46. Bunn PA Jr., Kelly K. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non-small cell lung cancer. Clin Lung Cancer. 2000;2(Suppl 1):S23-S28.